- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04571996
Blood-Brain Barrier Penetration of Therapeutic Agents in Human (BRIAN)
April 12, 2021 updated by: Orion Corporation, Orion Pharma
Blood-Brain Barrier Penetration of Therapeutic Agents in Human - an Exploratory Repeated Dose Pharmacokinetic Study in Patients With Idiopathic Normal Pressure Hydrocephalus Treated With Cerebroventricular Shunting
This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre.
Up to 6 evaluable subjects are planned.
The subjects will receive p.o. doses of ODM-104 for 5-7 days.
Single dose of paracetamol will be administered p.o. together with ODM-104 for purposes of comparison.
Study Overview
Study Type
Interventional
Enrollment (Actual)
4
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Turku, Finland
- CRST Turku
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent (IC) obtained before any study assessments are performed.
- Sufficient command of the Finnish language to be able to understand the subject information and to communicate with the study personnel.
- Males and females over 18 years of age.
- Body mass index (BMI) between 18-30 kg/m2.
- Idiopathic normal pressure hydrocephalus.
- Shunt surgery with cerebroventricular catheter placed at least 3 months earlier.
- Good general health, based on medical history, physical examination and laboratory assessments.
- Adequate mental status to give informed consent as assessed by the investigator and using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery.
- Female participants of child-bearing potential and male participants with female partners of child-bearing potential must adhere to a highly effective form of contraception (listed in Section 4.6) from the first study treatment administration until 1 month after the EoS visit.
Exclusion Criteria:
- Predicted poor compliance with study procedures, restrictions and requirements.
- Vulnerable subjects (i.e. persons under any administrative or legal supervision).
- Veins unsuitable for repeated venipuncture or cannulation
- Evidence of other current clinically significant cardiovascular, renal, hepatic, haematological, gastrointestinal, pulmonary, metabolicendocrine, neurological, urogenital or psychiatric disease than iNPH, as judged by the investigator.
- Type 1 diabetes mellitus.
- Diagnosis of cancer for which the subject is currently being treated, or for which there is evidence of active disease. Subjects with local prostate cancer or local dermatological tumours, such as basal or squamous cell carcinoma, may be included.
- Susceptibility to severe allergic reactions, e.g. history of anaphylactic shock due to any reason.
- Use of medications impacting the metabolism of dopamine, such as other COMT inhibitors (e.g. entacapone), levodopa and monoamine oxidase (MAO) inhibitors (e.g. rasagiline, selegiline), within 4 weeks before the first study drug administration.
- Any clinically significant abnormalities in screening laboratory test results, vital signs or physical examination findings that might influence the results of the study or cause a health risk for the subject if he/she takes part in the study.
- Any clinically significant 12-lead ECG abnormality, such as QTcF > 450 ms, after 10 min rest in supine position at the screening visit.
- Heart rate (HR) < 50 bpm or > 90 bpm, systolic blood pressure (BP) < 90 mmHg or > 160 mmHg, or diastolic BP < 50 mmHg or > 100 mmHg in supine or seated position after 10 min rest at the screening visit.
- Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).
- History of alcohol or drug abuse within the last 5 years, or current regular use of illicit drugs or excessive use of alcohol (regular alcohol drinking of more than 24 units/week for males or 14 units/week for females), or positive breath test for alcohol or positive urine test for drugs of abuse at screening or prior to the first IMP administration.
- Inability to refrain from consuming caffeine-containing beverages during the stay in the unit.
- Current use of nicotine-containing products, more than 5 cigarettes or equivalent/day, or inability to refrain from using nicotine-containing products during the stay at the study centre.
- Pregnant or lactating females.
- Participation in any other clinical drug study within 2 months before the first IMP administration of this study.
- Blood donation or loss of significant amount of blood within 2 months prior to the screening visit.
- Employee or first-degree relative of an employee of the contract research organization (CRST) or Orion.
- Any other condition that in the opinion of the investigator might interfere with the evaluation of the study results or constitute a health risk for the subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ODM-104 and Panadol Zapp
|
Capsule
Rapidly dissolving tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
In plasma / CSF
|
Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
Tmax
Time Frame: Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
In plasma / CSF
|
Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
AUC
Time Frame: Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
In plasma / CSF
|
Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
Cav
Time Frame: Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
In plasma / CSF
|
Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
M/P ratio
Time Frame: Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
In plasma / CSF
|
Daily PK samples during the first and last day of administration from day 1 to day 5-7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Orion Pharma Clinical Study Director, Orion Corporation, Orion Pharma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 29, 2020
Primary Completion (Actual)
February 23, 2021
Study Completion (Actual)
February 23, 2021
Study Registration Dates
First Submitted
September 25, 2020
First Submitted That Met QC Criteria
September 30, 2020
First Posted (Actual)
October 1, 2020
Study Record Updates
Last Update Posted (Actual)
April 13, 2021
Last Update Submitted That Met QC Criteria
April 12, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3112012
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CNS Disease
-
National Cancer Institute (NCI)WithdrawnRecurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
-
BiogenCompletedMultiple Sclerosis | Central Nervous System (CNS) Demyelinating DiseaseUnited Kingdom
-
Eisai Inc.Completed
-
GenmabBioNTech SERecruiting
-
AstraZenecaCompletedRecreational CNS Depressant UseCanada
-
Charite University, Berlin, GermanyPfizerUnknownRecurrent or Refractory Primary CNS LymphomaGermany
-
Arbor Pharmaceuticals, Inc.Active, not recruiting
-
Mayo ClinicRecruiting
-
Mayo ClinicEnrolling by invitation
-
Huashan HospitalUnited Imaging HealthcareRecruiting
Clinical Trials on ODM-104
-
Orion Corporation, Orion PharmaCompletedProstate CancerUnited States, United Kingdom, Finland, France, Estonia, Czech Republic
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaQuotient ClinicalCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompletedSolid TumoursFrance, Finland, Spain, Italy, Denmark, United Kingdom
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompletedProstate CancerUnited States, United Kingdom, Finland, France, Czech Republic, Estonia
-
BayerRecruitingCancerKorea, Republic of, Spain, United States, China, Australia, Austria, Belgium, Brazil, Colombia, Czechia, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Peru, Poland, Portugal, Romania, Russian... and more
-
Orion Corporation, Orion PharmaBayerCompleted
-
Aviceda Therapeutics, Inc.TerminatedDiabetic Retinopathy | Diabetic Macular EdemaUnited States